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RHEUMATOID ARTHRITIS
Rheumatoid arthritis (RA) is a chronic autoimmune
joint and soft tissue disease that affects approxi-
mately 0.5% to 1% of the world population.1 It is
a systemic inflammatory disease defined by poly-
articular synovitis, causing irreversible joint dam-
age and deformity, if not treated. Early diagnosis
and treatment of RA remain a major clinical chal-
lenge. No definite curative treatments are available
to date and the currently available drugs for RA
only delay the disease progression. Symptomatic
therapy and inflammation reduction with glucocor-
ticoids (GCs), methotrexate (MTX), nonsteroidal
anti-inflammatory drugs, azathioprine, tumor ne-
crosis factor-a blockers, and minocycline is
applied for symptomatic control of the disease.
The available medications used in the manage-
ment of RA cause various short- and long-term
side effects. Thus, there is a great need for biocom-
patible novel therapieswith high targeted efficiency
andminimal unwanted toxicity. Selective theranos-
tic agents have shown potential for targeted
imaging and therapy for inflamed joints, with the
least collateral toxicity to the healthy tissues.2,3
Glucocorticoid-Loaded Liposomes in
Rheumatoid Arthritis
As a well-documented anti-inflammatory drug,
GCs are being used widely in the management of
RA. However, they pose many side effects. To
reduce the systemic toxicity of GCs and to
enhance the RA treatment, encapsulation of GCs
into long-circulating liposomes (LCLs) has been
proposed. LCLs preferentially accumulate in the
inflamed tissue, allowing selective targeting to
diseased versus healthy tissue.
In-depth knowledge of the in vivo behavior of
LCLs with molecular imaging may offer a great
chance to monitor the drug biodistribution within
the host body. Besides, it will also allow clinicians
to select the best candidates for such therapies.
This might be of great importance, because the ki-
netic properties of LCLs vary widely among
different patients and also between different
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KEY POINTS
 Theranostic approaches combine a single agent’s therapeutic and diagnostic characteristics to
achieve a targeted molecular therapy, with little or no toxicity to normal tissues.
 Selective theranostic agents have shown potential for targeted imaging and therapy in a variety of
musculoskeletal illnesses.
 Some of these strategies include macrophage-related tools in inflammatory arthritis, chemokine re-
ceptor agents in multiple myeloma, and endothelial antibodies (TEM-1) in sarcoma.
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